Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cooper Companies Inc COO

The Cooper Companies, Inc. is a global medical device company. The Company operates in two business units: CooperVision and CooperSurgical. CooperVision segment is involved in the contact lens industry. CooperSurgical segment is involved in the fertility and women's health care market through its diversified portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. CooperVision’s products include MyDay daily disposable, MyDay daily disposable toric, MyDay Energys, MyDay multifocal, Biofinity & Biofinity XR, Biofinity Energys. CooperSurgical’s portfolio includes INSORB, Lone Star, and the Doppler Blood Flow Monitor. It also offers a suite of single-use cordless surgical retractors with an integrated multi-light-emitting diode (LED) light source and dual smoke evacuation channels, and single-use surgical suction devices with an integrated, cordless radial LED light source.


NDAQ:COO - Post by User

Bullboard Posts
Post by bc4uon Dec 06, 2012 5:15pm
326 Views
Post# 20694975

The Cooper Companies Announces Fourth Quarter and

The Cooper Companies Announces Fourth Quarter and

The Cooper Companies Announces Fourth Quarter and Full Year 2012 Results

PLEASANTON, Calif., Dec. 6, 2012 (GLOBE NEWSWIRE) -- The Cooper Companies, Inc. (NYSE:COO) today announced financial results for the fiscal fourth quarter and full year ended October 31, 2012.
• Fourth quarter revenue increased 10% year-over-year to $396.3 million. Fiscal 2012 revenue increased 9% to $1,445.1 million.
• Fourth quarter GAAP earnings per share (EPS) $1.46, up 31 cents or 27% from last year's fourth quarter. Fiscal 2012 GAAP EPS $5.05, up 39% from fiscal 2011.
• Fourth quarter non-GAAP EPS $1.47. Fiscal 2012 non-GAAP EPS $5.16. See "Reconciliation of Non-GAAP EPS to GAAP EPS" below.
• Fourth quarter free cash flow $83.5 million. Fiscal 2012 free cash flow $230.4 million.

Commenting on the results, Robert S. Weiss, Cooper's president and chief executive officer said, "I am pleased to report record financial results for fiscal 2012 including record revenues at both our business units and record EPS for the Company. We are proud of our many accomplishments throughout the year including CooperVision's success with its Biofinity® family of products, the re-launch of Avaira® Toric and the launch of a single-use silicone lens along with CooperSurgical's success within the surgical space and its acquisition of Origio. We continued to gain market share, post solid margins and maintain a strong balance sheet. As we enter fiscal 2013, we remain encouraged by our business trends and believe we are well positioned to deliver strong operating results."

Fourth Quarter GAAP Operating Highlights
• Revenue $396.3 million, up 10% from last year's fourth quarter, 7% excluding currency and acquisitions.
• Gross margin 64% compared with 62% in last year's fourth quarter. The improvement was primarily the result of increased manufacturing efficiencies, favorable product mix and the $6.0 million Avaira recall reserve for inventory and return provisions in last year's fourth quarter.
• Operating margin 20% compared with 18% in last year's fourth quarter. The improvement was the result of a higher gross margin and a $10.0 million one-time charge related to the settlement of the Rembrandt patent litigation that was included in last year's fourth quarter.
• Depreciation $23.5 million, up 13% from last year's fourth quarter. Amortization $7.3 million, up 31% from last year's fourth quarter primarily related to additional amortization from the acquisition of Origio.
• Total debt decreased $106.4 million from July 31, 2012, to $373.7 million. Interest expense $2.7 million compared with $2.9 million in last year's fourth quarter.
• Cash provided by operations $114.8 million, capital expenditures $32.6 million, and excluding acquisition costs of $1.3 million resulted in free cash flow of $83.5 million.

Fourth Quarter CooperVision (CVI) GAAP Operating Highlights
• Revenue $318.1 million, up 5% from last year's fourth quarter, 7% in constant currency.
• Revenue by category:

https://investor.coopercos.com/releasedetail.cfm?ReleaseID=725461


COO Chart
https://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=&insttype=Stock&symb=coo&time=6&startdate=1%2F4%2F1999&enddate=1%2F8%2F2012&freq=1&compidx=aaaaa%3A0&comptemptext=&comp=&ma=4&maval=9+15+50&uf=7168&lf=1&lf2=4&lf3=2&type=4&style=320&size=3&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=0&y=0

Analyst Estimates
https://www.marketwatch.com/investing/stock/coo/analystestimates

Bullboard Posts